ESSA Pharma Inc

Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Dec. 17, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. "We recently made the difficult decision to terminate the clinical development of masofaniten, and withdraw the related IND and CTAs, based on an interim analysis of the data from the Phase 2 combination study, concluding that masofaniten combined with enzalutamide was unlikely to meet its primary endpoint," said David Parkinson, MD, President and CEO of ESSA.» Mehr auf prnewswire.com

NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.» Mehr auf prnewswire.com

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.» Mehr auf accesswire.com